Journal Mobile Options
Table of Contents
Vol. 39, No. 1, 2001
Issue release date: January 2001
Eur Urol 2001;39:57–64

Comparison of the Clinical Validity of Free Prostate–Specific Antigen, Alpha–1 Antichymotrypsin–Bound Prostate–Specific Antigen and Complexed Prostate–Specific Antigen in Prostate Cancer Diagnosis

Lein M. · Lein M. · Jung K. · Jung K. · Elgeti U. · Elgeti U. · Petras T. · Petras T. · Stephan C. · Stephan C. · Brux B. · Brux B. · Sinha P. · Sinha P. · Winkelmann B. · Winkelmann B. · Schnorr D. · Schnorr D. · Loening S.A. · Loening S.A.
aDepartment of Urology and bInstitute of Laboratory Medicine and Pathobiochemistry, University Hospital Charité, Humboldt University, Berlin, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: To evaluate the diagnostic utility of free prostate specific antigen (fPSA), alpha–1– antichymotrypsin–bound PSA (PSA–ACT), complexed PSA (cPSA), and including their associated ratios to total PSA (tPSA) in serum for discrimination between prostate cancer (PCa) and benign prostatic hyperplasia (BPH). Methods: A total of 166 white men (age: 65–88 years) with a tPSA between 2 and 20 µg/l were retrospectively analysed. Serum concentrations of tPSA, fPSA, PSA–ACT and cPSA were measured in 118 untreated PCa patients and 48 patients with BPH. The tPSA and cPSA concentrations were measured with the Bayer Immuno 1 system (Bayer Diagnostics, Tarrytown, USA). The Elecsys system 2010 (Roche Diagnostics, Mannheim, Germany) was used for determination of tPSA and fPSA. The PSA–ACT assay is a newly, developed prototype assay on the ES system (Roche Diagnostics, Mannheim, Germany). Results: For statistical analysis only patients with tPSA between 2 and 20 µg/l were enrolled. The median concentrations of tPSA (Bayer: PCa 7.36 µg/l, BPH 4.03 µg/l; Roche: PCa 7.75, BPH 4.13), PSA–ACT (PCa 6.98, BPH 3.18) and cPSA (PCa 6.46, BPH 3.20) were significantly different. The median ratios of fPSA/tPSA (PCa 12.8 vs. BPH 22.4%), PSA–ACT/tPSA (PCa 89.8 vs. BPH 76.1%) and cPSA/tPSA (PCa 90.5 vs. BPH 81.7%) were significantly different between PCa and BPH patients. Using the areas under the curves, receiver operating characteristics analysis (tPSA: 2–20 µg/l) for discrimination between PCa and BPH showed that the ratios fPSA/tPSA (area under the curve: 0.77), PSA–ACT/tPSA (0.72) and cPSA/tPSA (0.78) were significantly different from tPSA (Bayer: 0.53; Roche: 0.55). PSA–ACT (0.64) and cPSA (0.59) alone were not significantly different from tPSA. The calculated ratios fPSA/tPSA, PSA–ACT/tPSA and cPSA/tPSA were not significantly different. Conclusion: The determination of PSA–ACT or cPSA and the associated ratios do not improve the diagnostic impact to discriminate between PCa and BPH compared to fPSA/tPSA ratio. The ratios PSA–ACT/tPSA or cPSA/tPSA can be considered to be alternative tools of fPSA/tPSA.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bostwick DG: Prostate–specific antigen: Current role in diagnostic pathology of prostate cancer. Am J Clin Pathol 1994;102:31–37.
  2. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000;50:7–33.
  3. Gee WF, Holtgrewe L, Albertsen PC, Litwin MS, Manyak MJ, O’Leary MP, Painter MR: Practice trends in the diagnosis and management of prostate cancer of prostate cancer. J Urol 1995;154:207–208.
  4. Catalona WJ: Measurement of prostate–specific antigen in serum as screening test for prostate cancer. N Engl J Med 1991;324:1156– 1161.
  5. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate–specific antigen and α1–antichymotrypsin is the major form of prostate–specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222–226.
  6. Catalona WJ: Clinical utility of measurements of free and total prostate–specific antigen (PSA): A review. Prostate 1996;7(suppl):64– 69.
  7. Christensson A, Björk T, Nilsson O, Dahlen U, Matikainen MT, Cockett ATK, Abrahamsson PA, Lilja H: Serum prostate specific antigen complexed to α1–antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100– 105.
  8. Björk T, Bjartell A, Abrahmasson PA, Hulkko S, di Sant’Agnese A, Lilja H: Alpha–1–antichymotrypsin production in PSA–producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994;43: 427–434.
  9. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274: 1214–1220.
  10. Lein M, Stephan C, Jung K, Schnorr D, Loening SA: Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: Which cutoff should be used? Cancer Invest 1998;16:45–49.
  11. Espana F, Royo M, Martinez M, Enguidanos MJ, Vera CD, Estelles A, Aznar J, Jimenez–Cruz F, Heeb MJ: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: Studies in serum and plasma samples. J Urol 1998;160:2081–2088.
  12. Lilja H, Christensson A, Dahlen U, Maitikainen MT, Nilson O, Pettersson K, Lövgren T: Prostate–specific antigen in serum occurs predominantly in complex with α1–antichymotrypsin. Clin Chem 1991;37:1618– 1625.
  13. Wu JT, Wilson L, Zhang P, Meikle AW, Stephenson R: Correlation of serum concentrations of PSA–ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J Clin Anal 1995;9:15–24.
  14. Heidtmann HH, Havemann K: Assay of complexed α1–antichymotrypsin in plasma. Clin Chem 1993;39:869–874.
  15. Wu JT, Liu GH: Advantages of replacing the total PSA assay with the assay for PSA–α1–antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal 1998;12:32–40.
  16. Pettersson K, Piironen T, Seppälä M, Liukkonen L, Christensson A, Matikainen MT, Suonpaa M, Lövgren T, Lilja H: Free and complexed prostate–specific antigen (PSA): In vitro stability, epitope map, and development of immunoflorometric assays for specific and sensitive detection of free PSA and PSA–α1–antichymotrypsin complex. Clin Chem 1995; 41:1480–1488.
  17. Björk T, Piironen T, Pettersson K, Lövgren T, Stenman UH, Oesterling JE, Abrahamsson PA, Lilja H: Comparison of analysis of the different prostate–specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 1996;48:882–888.
  18. Jung K, Brux B, Lein M, Knäbich A, Sinha P, Rudolph B, Schnorr D, Loening SA: Determination of alpha–1–antichymotrypsin–PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Urology 1999;53:1160– 1168.
  19. Jung K, Brux B, Knäbich A, Lein M, Sinha P, Schnorr D, Loening SA: A gap between total prostate–specific antigen and the sum of free prostate–specific antigen plus α1–antichymotrypsin–prostate–specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia. Clin Chem 1999; 45:422–425.
  20. Allard WJ, Zhou Z, Yeung KK: Novel immunoassay for the measurement of complexed prostate–specific antigen in serum. Clin Chem 1998;44:1216–1223.
  21. UICC: TNM Klassifikation maligner Tumoren, ed 4. Berlin, Springer, 1992, pp 141– 165.
  22. Lein M, Brux B, Jung K, Henke W, Koenig F, Stephan C, Schnorr D, Loening SA: Elimination of serum free and total prostate–specific antigen after radical retropubic prostatectomy. Eur J Clin Chem Clin Biochem 1997;35:591– 595.
  23. Passing H, Bablok W: A new biometrical procedure for testing the equality of measurements from two different analytical methods: Application of linear regression procedures for method comparison studies in clinical chemistry. Part 1. J Clin Chem Clin Biochem 1983; 21:709–720.
  24. Kiristo V, Poola A: Software for illustrative presentation of basic clinical characteristics of laboratory tests: GraphROC for Windows. Scand J Clin Lab Invest 1995;55(suppl 222): 43–60.
  25. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5–12.
  26. Ukimura O, Durrani O, Babaian RJ: Role of PSA and its indices in determining the need for repeated prostate biopsies. Urology 1997;50: 60–72.

    External Resources

  27. Oesterling JE, Jacobsen SJ, Klee GG, Petersson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lovgren T, Lilja H: Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090–1095.
  28. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH: Measurement of complex between prostate–specific antigen and alpha–protease inhibitor in serum. Clin Chem 1999;45:814–821.
  29. Stamey TA, Chen Z, Prestigiacomo AF: Reference material for PSA: The IFCC standardization study. Clin Biochem 1998;31:475–481.
  30. Brawer MK, Meyer GE, Letran JL, Bankson ER, Morris DL, Yeung KK, Allard WJ: Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52:372–378.
  31. Rittenhouse HG, Chan DW: Can complexed PSA be used as a single test for detecting prostate cancer? (editorial). Urology 1999;54: 4–5.
  32. Wang TJ, Linton HJ, Payne J, Rittenhouse HG, Chan DW, Partin AW, Wolfert RL, Kuus– Reichel K: Generation of PSA–ACT–specific monoclonal antibodies and their application in a sandwich immunoassay. Hybridoma 1999; 18:535–541.

    External Resources

  33. Filella X, Alcover J, Molina R, Corral JM, Carretero P, Ballesta AM: Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia. Prostate 2000;42:181–185.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50